IN2014DN02060A - - Google Patents

Info

Publication number
IN2014DN02060A
IN2014DN02060A IN2060DEN2014A IN2014DN02060A IN 2014DN02060 A IN2014DN02060 A IN 2014DN02060A IN 2060DEN2014 A IN2060DEN2014 A IN 2060DEN2014A IN 2014DN02060 A IN2014DN02060 A IN 2014DN02060A
Authority
IN
India
Prior art keywords
patient
benzimidazol
methylpiperazin
quinolin
tautomer
Prior art date
Application number
Other languages
English (en)
Inventor
Suraj Prakash Anand
Catherine Wynnette Reddick
Michael Shi
Mary Ellen Steed
Eugene Youchin Tan
Yongyu Wang
Mario Reinhard Stegert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN02060A publication Critical patent/IN2014DN02060A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2060DEN2014 2011-09-15 2012-09-07 IN2014DN02060A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535142P 2011-09-15 2011-09-15
PCT/US2012/054046 WO2013039764A1 (fr) 2011-09-15 2012-09-07 Utilisation de la 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one dans le traitement du cancer chez des patients atteints d'une insuffisance hépatique modérée

Publications (1)

Publication Number Publication Date
IN2014DN02060A true IN2014DN02060A (fr) 2015-05-15

Family

ID=46846036

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2060DEN2014 IN2014DN02060A (fr) 2011-09-15 2012-09-07

Country Status (12)

Country Link
US (1) US20140221389A1 (fr)
EP (1) EP2755655A1 (fr)
JP (1) JP2014526506A (fr)
KR (1) KR20140062485A (fr)
CN (1) CN103826634A (fr)
AU (1) AU2012308993A1 (fr)
BR (1) BR112014005653A2 (fr)
CA (1) CA2848210A1 (fr)
IN (1) IN2014DN02060A (fr)
MX (1) MX2014003182A (fr)
RU (1) RU2014114827A (fr)
WO (1) WO2013039764A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
EP3093014A1 (fr) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel et son utilisation pour le traitement du cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006711B1 (ru) 2000-09-11 2006-02-24 Чирон Корпорейшн Хинолиноновые производные в качестве ингибиторов тирозинкиназы
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
EP1565187A4 (fr) * 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic Procedes de traitement du cancer et procedes connexes
MXPA05012739A (es) * 2003-05-27 2006-05-17 Robert Per Hagerkvist Uso de inhibidor de quinasa de tirosina para tratar diabetes.
KR101368519B1 (ko) 2005-05-23 2014-02-27 노파르티스 아게 결정형 및 기타 형태의 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락트산염
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
JP6220126B2 (ja) * 2009-11-23 2017-10-25 セルリアン・ファーマ・インコーポレイテッド 治療的送達のためのシクロデキストリンに基づく重合体

Also Published As

Publication number Publication date
BR112014005653A2 (pt) 2017-03-28
RU2014114827A (ru) 2015-10-20
WO2013039764A1 (fr) 2013-03-21
CN103826634A (zh) 2014-05-28
AU2012308993A1 (en) 2014-03-27
EP2755655A1 (fr) 2014-07-23
CA2848210A1 (fr) 2013-03-21
KR20140062485A (ko) 2014-05-23
US20140221389A1 (en) 2014-08-07
JP2014526506A (ja) 2014-10-06
MX2014003182A (es) 2014-09-22

Similar Documents

Publication Publication Date Title
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
PH12015501965B1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
UA118759C2 (uk) Сполуки 3,4-дигідроізохінолін-2(1н)-ілу
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
UA115231C2 (uk) Сполуки імідазопіролідинонів
IN2014MN00988A (fr)
IN2014MN01640A (fr)
WO2012173682A3 (fr) Composés et méthodes de traitement de maladies liées à l'isocitrate déshydrogénase
NZ709153A (en) Pyrimidinone derivatives having human neutrophil elastase inhibitory activity
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
IN2014DN10670A (fr)
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
EA201391171A1 (ru) Формы рифаксимина и их применение
IN2015MN00002A (fr)
MX2018002885A (es) Sales de inhibidor de pim cinasa.
WO2014160281A3 (fr) Procédé pour améliorer l'administration de composés thérapeutiques à l'œil
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
MX2016004967A (es) Tratamiento para cancer pancreatico.
UA109942C2 (ru) Производные 2-амино-3-(имидазол-2-ил)-пиридин-4-она и их применение как ингибиторов киназы рецептора vegf
PH12014502065A1 (en) Vesicular formulations
IN2014DN02060A (fr)
EA033124B1 (ru) Применение конденсированного бициклического 2,4-диаминопиримидинового производного для лечения alk- или fak-опосредованного заболевания или нарушения у субъекта
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions